DoseGear research brief
Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12. 4% weight reduction at 72 weeks.
DG Peptide Protocols
Extensively StudiedWeight LossMetabolic
Orforglipron
LY-3502970
Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
Research overview
Mechanism of action
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Synthetic nonpeptide GLP-1-receptor agonist.
What it is researched for
Type 2 diabetes and obesity research through GLP-1-receptor activation.
Research observation window
Not reported within the injectable-vial scope.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
No sourced lyophilized-vial injectable protocol is listed for this profile.
Safety context
Reported side effects
- Diarrhea (more prevalent than with injectable GLP-1s)
- Nausea (typically improves after first month)
- Appetite reduction
Contraindications & cautions
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy and breastfeeding
Scientific references
- 01
ATTAIN-1 Phase 3 Trial (Obesity)
Scientific citationATTAIN-1 Phase 3 Trial (Obesity). (2025). - 02
ATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes)
Scientific citationATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes). (2025). - 03
ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes)
Scientific citationACHIEVE-1 Phase 3 Trial (Type 2 Diabetes). (2025). - 04
Phase 2 Obesity Study
Scientific citationPhase 2 Obesity Study. (2023).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.